AMGEN INC., ET AL., PETITIONERS v. SANOFI, ET AL., 598 U.S. 594

Summary

HOLDINGS: [1]-The patents claiming a monopoly over all antibodies that bound to specific amino acids on a specific naturally occurring protein and blocked that protein from impairing the body's mechanism for removing LDL cholesterol from the bloodstream failed to meet the enablement requirement of 35 U.S.C.S. § 112(a) where the described roadmap or proposal for conservative substitution for finding functional antibodies forced scientists to engage in random trial-and-error discovery.